350 related articles for article (PubMed ID: 25453994)
1. Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.
Thomson BK; Nolin TD; Velenosi TJ; Feere DA; Knauer MJ; Asher LJ; House AA; Urquhart BL
Am J Kidney Dis; 2015 Apr; 65(4):574-82. PubMed ID: 25453994
[TBL] [Abstract][Full Text] [Related]
2. Brain atrophy in peritoneal dialysis and CKD stages 3-5: a cross-sectional and longitudinal study.
Tsuruya K; Yoshida H; Kuroki Y; Nagata M; Mizumasa T; Mitsuiki K; Yoshiura T; Hirakawa M; Kanai H; Hori K; Hirakata H; Kitazono T
Am J Kidney Dis; 2015 Feb; 65(2):312-21. PubMed ID: 25218680
[TBL] [Abstract][Full Text] [Related]
3. ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
Nolin TD; Frye RF; Le P; Sadr H; Naud J; Leblond FA; Pichette V; Himmelfarb J
J Am Soc Nephrol; 2009 Oct; 20(10):2269-76. PubMed ID: 19696225
[TBL] [Abstract][Full Text] [Related]
4. Association between body mass index and body fat in chronic kidney disease stages 3 to 5, hemodialysis, and peritoneal dialysis patients.
Leinig C; Pecoits-Filho R; Nascimento MM; Gonçalves S; Riella MC; Martins C
J Ren Nutr; 2008 Sep; 18(5):424-9. PubMed ID: 18721737
[TBL] [Abstract][Full Text] [Related]
5. Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With End-Stage Renal Disease.
Egeland EJ; Witczak BJ; Zaré HK; Christensen H; Åsberg A; Robertsen I
Clin Pharmacol Ther; 2020 Oct; 108(4):866-873. PubMed ID: 32356565
[TBL] [Abstract][Full Text] [Related]
6. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.
Robertson SM; Davey RT; Voell J; Formentini E; Alfaro RM; Penzak SR
Curr Med Res Opin; 2008 Feb; 24(2):591-9. PubMed ID: 18205997
[TBL] [Abstract][Full Text] [Related]
7. Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients.
Vanhove T; Bouillon T; de Loor H; Annaert P; Kuypers D
Clin Pharmacol Ther; 2017 Dec; 102(6):989-996. PubMed ID: 28437851
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
Ieiri I; Tsunemitsu S; Maeda K; Ando Y; Izumi N; Kimura M; Yamane N; Okuzono T; Morishita M; Kotani N; Kanda E; Deguchi M; Matsuguma K; Matsuki S; Hirota T; Irie S; Kusuhara H; Sugiyama Y
J Clin Pharmacol; 2013 Jun; 53(6):654-61. PubMed ID: 23381882
[TBL] [Abstract][Full Text] [Related]
9. CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease.
Wilson A; Tirona RG; Kim RB
Inflamm Bowel Dis; 2017 May; 23(5):804-813. PubMed ID: 28301431
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.
Velenosi TJ; Urquhart BL
Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1131-43. PubMed ID: 24961255
[TBL] [Abstract][Full Text] [Related]
11. In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.
Joy MS; Frye RF; Nolin TD; Roberts BV; La MK; Wang J; Brouwer KL; Dooley MA; Falk RJ
Pharmacotherapy; 2014 Feb; 34(2):114-22. PubMed ID: 24038489
[TBL] [Abstract][Full Text] [Related]
12. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
[TBL] [Abstract][Full Text] [Related]
13. The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans.
Imanaga J; Kotegawa T; Imai H; Tsutsumi K; Yoshizato T; Ohyama T; Shirasaka Y; Tamai I; Tateishi T; Ohashi K
Pharmacogenet Genomics; 2011 Feb; 21(2):84-93. PubMed ID: 21280267
[TBL] [Abstract][Full Text] [Related]
14. Ambulatory blood pressure profile and blood pressure variability in peritoneal dialysis compared with hemodialysis and chronic kidney disease patients.
Alexandrou ME; Loutradis C; Schoina M; Tzanis G; Dimitriadis C; Sachpekidis V; Papadopoulou D; Gkaliagkousi Ε; Papagianni A; Parati G; Sarafidis P
Hypertens Res; 2020 Sep; 43(9):903-913. PubMed ID: 32327730
[TBL] [Abstract][Full Text] [Related]
15. Killer cell immunoglobulin receptor profile on CD4(+) CD28(-) T cells and their pathogenic role in non-dialysis-dependent and dialysis-dependent chronic kidney disease patients.
Zal B; Chitalia N; Ng YS; Trieu V; Javed S; Warrington R; Kaski JC; Banerjee D; Baboonian C
Immunology; 2015 May; 145(1):105-13. PubMed ID: 25484131
[TBL] [Abstract][Full Text] [Related]
16. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants.
Malati CY; Robertson SM; Hunt JD; Chairez C; Alfaro RM; Kovacs JA; Penzak SR
J Clin Pharmacol; 2012 Jun; 52(6):932-9. PubMed ID: 21646440
[TBL] [Abstract][Full Text] [Related]
17. Dialysis-related transcriptomic profiling: the pivotal role of heparanase.
Zaza G; Masola V; Granata S; Pontrelli P; Sallustio F; Gesualdo L; Gambaro G; Grandaliano G; Lupo A
Exp Biol Med (Maywood); 2014 Jan; 239(1):52-64. PubMed ID: 24189015
[TBL] [Abstract][Full Text] [Related]
18. Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants.
Xiao CQ; Chen R; Lin J; Wang G; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2012 Feb; 42(2):173-8. PubMed ID: 21943317
[TBL] [Abstract][Full Text] [Related]
19. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
20. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
